Aflibercept Eylea®
The SHIKARI® Aflibercept portfolio provides one quantitative free-drug assay plus quantitative and qualitative anti-aflibercept antibody assays for human serum or plasma.
Why Aflibercept is relevant to biological-drug monitoring research
Aflibercept has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Aflibercept is a recombinant VEGF-receptor fusion protein that acts as a soluble decoy receptor for VEGF-A and placental growth factor (PlGF). Source ↗
Approved Indications
EMA-authorised ophthalmic uses include neovascular age-related macular degeneration and other retinal disorders driven by pathological vascular leakage or neovascularisation, including diabetic macular oedema and retinal-vein-occlusion-associated macular oedema. EMA source ↗
Systemic Exposure After Intravitreal Dosing
Systemic free-aflibercept concentrations after intravitreal dosing are very low and should not be interpreted as ocular therapeutic targets:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Aflibercept research assays
Ligand-binding ELISA for quantitative analysis of free aflibercept in human serum or plasma.
Quantitative ELISA for anti-aflibercept antibodies in human serum or plasma, including the assay-specific confirmation procedure.
Qualitative ELISA for positive or negative assessment of anti-aflibercept antibodies in human serum or plasma according to assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-AF | AFL-FD-EYL | Quantitative | Free aflibercept | Human serum / plasma | 5 µL | 105 min | LOD 10; LOQ 30 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATAF | AFL-QNS-EYL | Quantitative | Anti-aflibercept antibodies | Human serum / plasma | 50 µL | 110 min | LOD 1; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATAF | AFL-QLS-EYL | Qualitative | Anti-aflibercept antibodies | Human serum / plasma | 20 µL | 140 min | Positive; negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Aflibercept Literature and Product-Use Records
Planning a Aflibercept research study?
Matrix Biotek can help identify the appropriate Aflibercept assay and prepare regional quotation and delivery information.